The normal force between two particles with De = 6.30 mm for different aspect ratios and sphericities: (a) hertz normal contact force; (b) normal viscous contact force. by Yongfeng Zhu (7361045)

Subjects:

The force chain distributions of different numerical samples composed of elongated ellipsoids with different particle morphologies and particle sizes before shearing and after load... by Yongfeng Zhu (7361045)

Subjects:

The tangential force between two particles with different aspect ratios and sphericities for De = 6.30 mm: (a) elastic tangential contact force; (b) viscous tangential contact forc... by Yongfeng Zhu (7361045)

Subjects:

Critical state parameters obtained from DEM simulations. by Yongfeng Zhu (7361045)

Subjects:

The tangential force between two particles with different equivalent diameters for P3: (a) elastic tangential contact force; (b) viscous tangential contact force. by Yongfeng Zhu (7361045)

Subjects:

The effects of CGA on NLRP3 inflammasome and the Nrf2 pathway in high-fat diet (HFD)/ streptozotocin (STZ) -induced diabetic kidneys. by Liping Bao (2936715)

Subjects:

The effects of CGA on NLRP3 inflammasome and the Nrf2 pathway in HK-2 cells. by Liping Bao (2936715)

Subjects:

The biochemical data and protein expression levels. by Liping Bao (2936715)

Subjects:

Effects of CGA on renal biochemical markers. by Liping Bao (2936715)

Subjects:

The effects of CGA on renal histopathological injury. by Liping Bao (2936715)

Subjects:

Intervention in the CGA-induced activation of the Nrf2 pathway and its inhibition of NLRP3 inflammasome in HK-2 cells. by Liping Bao (2936715)

Subjects:

Forest Plot of Multivariate Odds Ratios for Risk Factors Associated with Nerve Injury 90 Days After Total Knee Arthroplasty. by Rahul H. Jayaram (21463899)

Subjects:

Univariate and Multivariate analysis of risk factors for nerve injury 90-days after TKA. by Rahul H. Jayaram (21463899)

Subjects:

Change in Watt’s Connectedness Scale, Subscales by Treatment Group. by Benjamin R. Lewis (22279166)

Subjects:

Primary and secondary efficacy end points (intention-to-treat population). by Benjamin R. Lewis (22279166)

Subjects:

Demographic and clinical characteristics of participants at baseline. by Benjamin R. Lewis (22279166)

Subjects:

Study-related adverse events. by Benjamin R. Lewis (22279166)

Subjects:

Study flow chart. by Benjamin R. Lewis (22279166)

Subjects:

Change in QIDS-SR-16 and MBI-HSS-MP by Treatment Group. by Benjamin R. Lewis (22279166)

Subjects:

Study CONSORT diagram. by Benjamin R. Lewis (22279166)

Subjects: